Trial
NCT00801125
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
Elan Pharmaceuticals
Condition
Crohn's Disease
Intervention
natalizumab
Why stopped
Study sponsor decided to withdraw the current study prior to enrollment of first participant.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-06-16